Plus Therapeutics, Inc. (PSTV) Financial Statements
Industry: Surgical & Medical Instruments & Apparatus
In fiscal 2025, Plus Therapeutics reported revenue of $5.2M, down 10.5% from $5.8M the year before. Net income was -$22.4M (a -429.4% net margin), or -$7.25 per diluted share. Operating margin was -293.5%. Operating activities generated -$20.8M of cash, leaving -$20.9M of free cash flow. At fiscal year end, Plus Therapeutics held $16.3M in total assets against $12.3M in total liabilities, including $4.3M of cash and equivalents.
Open the full interactive Plus Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Plus Therapeutics Key Stats
| Share Price | $1.74 |
|---|---|
| Market Cap | $12.0M |
| Revenue YoY Growth | -10.5% |
| 52-Week Range | $1.56 – $18.00 |
| Shares Outstanding | 6.9 million (basic, 2026 Q2) |
Plus Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $5.8M | $5.2M |
| Operating Income | -$9.6M | -$12.5M | -$19.7M | -$13.3M | -$14.7M | -$15.3M |
| Pre-Tax Income | -$8.2M | -$13.4M | -$20.3M | -$13.3M | -$13.0M | -$22.4M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$8.2M | -$13.4M | -$20.3M | -$13.3M | -$13.0M | -$22.4M |
| Diluted EPS | -$697.50 | -$416.25 | -$288.75 | -$106.00 | -$58.50 | -$7.25 |
Plus Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $1.4M | $1.4M | $1.0M | $411,000 |
| Net Income | -$4.4M | -$5.7M | -$6.9M | -$9.0M |
| Diluted EPS | -$1.00 | -$0.07 | -$1.05 | -$1.31 |
Plus Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.3M | $18.4M | $18.1M | $8.6M | $76,000 | $4.3M |
| Current Assets | $9.2M | $19.7M | $21.8M | $9.8M | $5.3M | $15.2M |
| Total Assets | $12.1M | $22.0M | $23.9M | $11.4M | $6.6M | $16.3M |
| Current Liabilities | $8.5M | $5.9M | $11.9M | $10.7M | $15.6M | $12.3M |
| Total Long-Term Debt | $12.7M | $6.6M | $5.4M | $4.0M | — | — |
| Total Liabilities | $9.1M | $11.1M | $17.4M | $12.7M | $15.6M | $12.3M |
| Shareholders' Equity | $3.0M | $10.8M | $6.4M | -$1.3M | -$8.9M | $4.0M |
Plus Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$8.4M | -$10.3M | -$13.0M | -$12.9M | -$10.6M | -$20.8M |
| Cash From Investing | -$493,000 | -$82,000 | -$759,000 | -$160,000 | -$4.1M | -$854,000 |
| Cash From Financing | -$319,000 | $20.4M | $13.5M | $3.4M | $6.2M | $30.3M |
| Free Cash Flow | — | -$10.3M | -$13.0M | -$12.9M | -$10.7M | -$20.9M |
Figures from Plus Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Plus Therapeutics financials page for every line item.
Plus Therapeutics Company Profile
| Ticker | PSTV |
|---|---|
| Exchange | Nasdaq |
| Industry | Surgical & Medical Instruments & Apparatus |
| Headquarters | Houston, Texas |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001095981 |
Frequently Asked Questions
What was Plus Therapeutics' revenue in fiscal 2025?
Plus Therapeutics (PSTV) reported revenue of $5.2M for fiscal 2025.
What is Plus Therapeutics' annual revenue history?
Plus Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $5.8M; 2025: $5.2M.
What was Plus Therapeutics' net income in fiscal 2025?
Plus Therapeutics reported net income of -$22.4M for fiscal 2025.
What was Plus Therapeutics' earnings per share (EPS) in fiscal 2025?
Plus Therapeutics' diluted EPS was -$7.25 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Plus Therapeutics generate in fiscal 2025?
Plus Therapeutics generated -$20.9M of free cash flow in fiscal 2025.
What was Plus Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Plus Therapeutics reported revenue of $411,000.
How many shares of Plus Therapeutics are outstanding?
Plus Therapeutics reported a weighted average of 6.9 million basic shares outstanding in 2026 Q2.
What is Plus Therapeutics' market cap?
Based on its latest closing price, Plus Therapeutics (PSTV) has a market capitalization of about $12.0M.
When does Plus Therapeutics' fiscal year end?
Plus Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Plus Therapeutics headquartered?
Plus Therapeutics lists its business address in Houston, Texas in its SEC filings.
Plus Therapeutics Competitors & Similar Companies
See all 109 Surgical & Medical Instruments & Apparatus companies →